IFNB1 and myeloid sarcoma: However, while MS is frequently treated with disease-modifying immunotherapy, case series indicate that several MS treatments (interferon beta, glatiramer acetate and natalizumab) do not suppress relapses and might exacerbate MOGAD (20, 21, 23, 24, 48).